SPY331.83+1.77 0.54%
DIA271.33+2.92 1.09%
IXIC10,980.26+39.10 0.36%

Horizon Therapeutics Announces 79% Of Patients Achieved A Complete Response In MIRROR Open-Label Pilot Study, Supporting KRYSTEXXA Immunomodulation Strategy To Optimize Treatment Outcomes

Benzinga · -